Home › Myelofibrosis › North Carolina
Myelofibrosis clinical trials in North Carolina
19 studies for Myelofibrosis are looking for participants at sites in North Carolina.
Cities in North Carolina
Study of INCA036978 in Participants With Myeloproliferative Neoplasms
- University of North Carolina At Chapel Hill, Chapel Hill
- Levine Cancer Institute, Charlotte
- Duke University Medical Center, Department of Hematologic Malignancies and Cellular Therapy, Durham
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Nov 13, 2026 · NCT07441694A Phase 1 Study of LY5830966 in Participants With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (PPV-MF), or Post-Essential Thrombocythemia Myelofibrosis (PET-MF) Who Have Been Failed by a Type I JAK2 Inhibitor (JAK2i)
- Levine Cancer Institute, Charlotte
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Nov 12, 2026 · NCT06343805A Study to Evaluate Safety and Efficacy of Bomedemstat (MK-3543-017)
- DUHS Duke Blood Cancer Center ( Site 6005), Durham
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Nov 10, 2026 · NCT06351631A Study to Compare Elritercept to Placebo in Adults With Myelofibrosis and Anemia Who Are Taking Ruxolitinib
- Duke Blood Cancer Center, Durham
- Novant Health, Winston-Salem
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Nov 6, 2026 · NCT07623161Tissue, Blood, and Body Fluid Sample Collection From Patients With Hematologic Cancer
- Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill, Chapel Hill
RecruitingObservational study
Ages 18 to 120 · All sexes · Updated Oct 28, 2026 · NCT01137643A Randomized Study of ASTX727 With or Without Iadademstat in Advanced Myeloproliferative Neoplasms (MPNs)
- Carolinas Medical Center/Levine Cancer Institute, Charlotte
- Atrium Health Cabarrus/LCI-Concord, Concord
- Wake Forest University Health Sciences, Winston-Salem
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Oct 27, 2026 · NCT06661915A Study to Evaluate DMR-001 in Participants With CALR-mutant Myeloproliferative Neoplasms
- Site US14, Charlotte
- Site US24, Durham
- Site US13, Winston-Salem
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Oct 27, 2026 · NCT07849231Selinexor and Pacritinib in JAK Inhibitor-naïve MF Patients With Cytopenias
- Wake Forest Baptist Health Comprehensive Cancer Center, Winston-Salem
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Oct 27, 2026 · NCT07447817Study of DISC-0974 (RALLY-MF) in Participants With Myelofibrosis or Myelodysplastic Syndrome and Anemia
- Atrium Health Wake Forest Baptist, Winston-Salem
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Oct 22, 2026 · NCT05320198A Study of Oral Nuvisertib (TP-3654) in Patients With Myelofibrosis
- Duke Cancer Institute, Durham
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Oct 2, 2026 · NCT04176198A Study to Evaluate INCA035784 in Participants With Myeloproliferative Neoplasms
- University of North Carolina At Chapel Hill, Chapel Hill
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Aug 6, 2026 · NCT07008118Registry of Older Patients With Cancer
- Seby B. Jones Cancer Center, Boone
- Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill, Chapel Hill
- East Carolina University, Greenville
- and 4 more
RecruitingObservational study
Ages 65 and older · All sexes · Updated Jun 29, 2026 · NCT01137825Reparixin in Patients With Myelofibrosis Myeloproliferative Neoplasms Research Consortium (MPN-RC 120)
- Wake Forest Baptist Health Comprehensive Cancer Center, Winston-Salem
RecruitingPhase 2
Ages 18 and older · All sexes · Updated May 6, 2026 · NCT05835466Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.
- University of North Carolina, Chapel Hill
RecruitingPhase 1
Ages 13 and older · All sexes · Updated May 5, 2026 · NCT04771572A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasms
- Wake Forest Baptist Medical Center, Winston-Salem
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Apr 17, 2026 · NCT06034002A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation
- University of North Carolina, Chapel Hill
RecruitingPhase 2
Ages 18 to 66 · All sexes · Updated Mar 17, 2026 · NCT06859424A Study of Selinexor Monotherapy in Subjects With JAK Inhibitor-naïve Myelofibrosis and Moderate Thrombocytopenia
- Duke University, Durham
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Feb 12, 2026 · NCT05980806SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, Chapel Hill
- Massive Bio SYNERGY-AI site, Winston-Salem
RecruitingObservational study
All ages · All sexes · Updated Oct 28, 2025 · NCT03452774Study of Navtemadlin add-on to Ruxolitinib in JAK Inhibitor-Naïve Patients With Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib
- Medical University of South Carolina (MUSC), Charleston
- Atrium Health Levine Cancer Institute, Charlotte
- Duke University Medical Center, Durham
- and 2 more
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 25, 2025 · NCT06479135From ClinicalTrials.gov, data retrieved Nov 15, 2026. Each study sets its own eligibility; the study team decides who can join.